Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 19, 2025Panacea Journal of Medical SciencesOpen Access

Study of adverse drug reactions (ADR’S) requiring change in anti-tubercular regimen in multi-drug resistant tuberculosis (MDR-TB) patients in a tertiary healthcare centre

View Full Paper
Ask AI
Bookmark
Share

Authors

AUAyalur Kodakara Kochugovindan UnniPMPriti MeshramVPVishwanath Pujari

Discussion

Loading...

Member takes

Implication

Observational study identifies severe adverse drug reactions in MDR-TB patients, suggesting impact on treatment adherence.

Key Points

  • Sixty MDR-TB patients experienced regimen changes due to severe adverse drug reactions, affecting treatment adherence.
  • The most frequently withheld drug was Linezolid, noted in 61.67% of cases, followed by others like Cycloserine and Bedaquiline.
  • Conducted as an observational study, it focused on patients during a year-long follow-up period in Mumbai.
  • The findings highlight the critical need to monitor adverse reactions to maintain adherence in MDR-TB treatment.

Cite This Study

Unni et al. (2025) studied this question.

synapsesocial.com/papers/68af35d5cf1dd9ea359e97f9https://doi.org/10.18231/pjms.v.15.i.2.289-291
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Patterns of adverse drug reactions and treatment outcomes in drug-resistant tuberculosis: A retrospective study from a tertiary care hospital in Delhi2025
  2. 2Adverse Drug Reactions due to Antitubercular Therapy in Multidrug-Resistant Tuberculosis in Meghalaya, India2025
  3. 3Retrospective assessment of adverse drug reactions linked to first-line antituberculosis drugs at a tertiary healthcare facility in Northern India2025
  4. 4Evaluating Treatment Outcomes in Special Populations with Multidrug- and Extensively Drug-Resistant Tuberculosis: A Comparative Cohort Study2025
  5. 5Adverse drug reactions to the nine-month all-oral and 18-month regimens for multidrug-resistant tuberculosis in Indonesia2025 · 1 citations